Lasofoxifene
From Wikipedia, the free encyclopedia
 |
|
|
Lasofoxifene
|
|
| Systematic (IUPAC) name | |
| (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol | |
| Identifiers | |
| CAS number | |
| ATC code | G03 |
| PubChem | |
| Chemical data | |
| Formula | C28H31NO2 |
| Mol. mass | 413.55 or 563.64 (with tartrate) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.[1]
In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.
On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.
[edit] References
- ^ Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs 15 (9): 1091–103. doi:. PMID 16916275.
[edit] External links
- Reference site for lasofoxifene information. Anakena Internet Services SL. Retrieved on 2008-03-18.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
